MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · Real-Time Price · USD
40.02
+1.70 (4.42%)
Apr 21, 2025, 4:00 PM EDT - Market closed
4.42%
Market Cap 2.53B
Revenue (ttm) n/a
Net Income (ttm) -118.94M
Shares Out 63.28M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 345,770
Open 39.00
Previous Close 38.33
Day's Range 39.00 - 40.07
52-Week Range 31.42 - 58.26
Beta 1.31
Analysts Strong Buy
Price Target 80.50 (+101.15%)
Earnings Date May 6, 2025

About MLTX

MoonLake Immunotherapeutics, a clinical stage biopharmaceutical company, engages in developing therapies. The company develops Sonelokimab, a novel tri-specific investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 100
Stock Exchange NASDAQ
Ticker Symbol MLTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for MLTX stock is "Strong Buy." The 12-month stock price forecast is $80.5, which is an increase of 101.15% from the latest price.

Price Target
$80.5
(101.15% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MoonLake Immunotherapeutics: A Buy At Dips

MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite mixed r...

13 days ago - Seeking Alpha

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today...

18 days ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflamma...

7 weeks ago - GlobeNewsWire

MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon

MoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies using sonelokimab to target moderate-to-severe Hidradenitis Suppurativa patients in mid-2025. The ...

3 months ago - Seeking Alpha

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulos...

3 months ago - GlobeNewsWire

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stag...

8 months ago - GlobeNewsWire

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 20...

9 months ago - Seeking Alpha

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion

MoonLake develops sonelokimab, targeting large markets like psoriasis and hidradenitis suppurativa, with promising Phase 2 data. Despite a competitive landscape with established IL-17 inhibitors, Moon...

1 year ago - Seeking Alpha

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program...

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

SAN FRANCISCO & ZUG, Switzerland--(BUSINESS WIRE)--MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat...

1 year ago - Business Wire

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody ® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Is A Promising Bet On Psoriasis Treatment

MoonLake Immunotherapeutics is a Swiss biopharmaceutical company focused on nanobody development with its drug Sonelokimab. Sonelokimab has shown positive results in clinical trials for psoriasis, hid...

1 year ago - Seeking Alpha

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing t...

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ® sonelokimab in active psoriatic arthritis

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody ® sonelokimab as a highly promising and differentiated therapeutic solution for H...

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody ® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology C...

1 year ago - GlobeNewsWire

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody ® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatolog...

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Is Now Thoroughly De-Risked

MoonLake Immunotherapeutics has seen success in the last 5 months after positive data from a phase 2 trial of sonelokimab in hidradenitis suppurativa. Sonelokimab has shown promising results in treati...

1 year ago - Seeking Alpha

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

MoonLake Immunotherapeutics to ho st a Capital Markets Day on Monday , September 11

1 year ago - GlobeNewsWire

Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)

MoonLake Immunotherapeutics' financial health improved with $501.8M cash reserves and robust Q2 2023 research advancements. MLTX focuses on sonelokimab's potential in treating HS, collaborating with S...

1 year ago - Seeking Alpha